Genetic Associations with Ascending Aorta Dilatation

Established Genetic Causes

• The American Heart Association recommends genetic testing for aortopathy, focusing on established genes such as FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, and MYH11, rather than MEF2C 1, 2, 3, 4, 5, 6
• Marfan syndrome, caused by FBN1 gene mutations, is a well-documented cause of aortic dilatation, according to the American College of Cardiology 5, 6
• Loeys-Dietz syndrome, resulting from TGFBR1, TGFBR2, SMAD3, TGFB2, and TGFB3 gene mutations, is also a known cause of aortic dilatation, as stated by the American Heart Association 5, 6
• Vascular Ehlers-Danlos syndrome, caused by COL3A1 gene mutations, is another established genetic cause of aortic dilatation, as recommended by the American College of Medical Genetics 5, 6
• Non-syndromic FTAAD, associated with ACTA2, MYH11, and MYLK mutations, is a significant genetic cause of aortic dilatation, according to the American Heart Association 3, 5, 6

Clinical Implications and Management

• The American College of Cardiology recommends that first-degree relatives of patients with thoracic aortic aneurysm/dissection undergo aortic imaging to identify asymptomatic disease 3
• If a known pathogenic mutation is identified, only relatives with the same mutation need regular aortic imaging, as stated by the American Heart Association 3

Monitoring and Management Recommendations

• The American College of Cardiology recommends echocardiography as the primary imaging modality for monitoring aortic dimensions 1, 2
• CMR is indicated when echocardiography cannot adequately visualize the aortic root or ascending aorta, according to the American Heart Association 5, 6
• Annual echocardiograms are recommended for individuals with small aortic dimensions and slow rate of dilation, as stated by the American College of Medical Genetics 1, 4
• More frequent imaging (every 6 months) is recommended if the aortic root exceeds 4.5 cm, growth rate exceeds 0.5 cm/year, or significant aortic regurgitation develops, according to the American College of Cardiology 1, 4
• β-blockade therapy is recommended for aortic root dilation, as stated by the American Heart Association 1, 4

Genetic Basis and Clinical Utility of GeneDx Clinical Exome Sequence Analysis for Aortopathies

Genetic Heterogeneity and Exome Sequencing

• Thoracic aortic aneurysms and dissections (TAAD) have significant genetic heterogeneity, with multiple genes capable of causing similar clinical presentations 7, 8
• The American Heart Association recommends exome sequencing for patients with aortic dilatation to identify known pathogenic variants in established genes (FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, MYH11) 8

Clinical Utility of Genetic Testing

• Genetic testing helps identify the underlying cause of aortic dilatation, which has important implications for risk stratification, with certain genetic variants (e.g., TGFBR2) associated with aortic dissection at smaller diameters (<5.0 cm) 9, 10
• The American College of Cardiology recommends genetic testing to guide surgical timing, with patients with specific genetic disorders potentially requiring earlier surgical intervention 10, 11
• Genetic testing also informs family screening, with only relatives with the same pathogenic mutation requiring regular aortic imaging 8

Specific Genes and Recommendations

• The American Heart Association recommends sequencing ACTA2 in patients with a family history of thoracic aortic aneurysms/dissections (Class IIa recommendation) 12, 13
• TGFBR1, TGFBR2, and MYH11 may be considered for sequencing in patients with appropriate clinical features (Class IIb recommendation) 14
• FBN1 is associated with Marfan syndrome, and its identification has implications for patient management 15

Screening Guidelines for Familial Thoracic Aortic Aneurysms

Immediate Screening Recommendations

• The American Heart Association recommends that a 19-year-old patient with multiple affected first-degree and second-degree relatives should undergo immediate thoracic aortic imaging with transthoracic echocardiography (TTE), and genetic testing should be strongly considered given the pattern suggesting familial thoracic aortic disease 16, 17
• Transthoracic echocardiography (TTE) is the recommended first-line imaging modality to evaluate for asymptomatic thoracic aortic dilatation or aneurysm 16, 17
• If TTE cannot adequately visualize the aortic root or ascending aorta, cardiovascular magnetic resonance (CMR) or computed tomography (CT) should be performed 18
• The presence of three affected relatives across two generations strongly suggests familial thoracic aortic aneurysm and dissection (FTAAD), which warrants screening regardless of the patient's young age 16, 17, 19

Genetic Testing Strategy

• Genetic testing should be pursued for established aortopathy genes including FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, and MYH11 16, 17
• The affected father should ideally undergo genetic testing first; if a pathogenic variant is identified, cascade testing of the 19-year-old can confirm or exclude the mutation 16, 17
• ACTA2 gene sequencing is particularly reasonable given the family history pattern (Class IIa recommendation) 19

Critical Clinical Context

• Thoracic aortic disease with familial patterns follows different epidemiology and requires earlier surveillance 16, 17
• Familial thoracic aortic aneurysms can present at younger ages than sporadic cases, and dissections can occur at smaller aortic diameters, particularly with certain genetic mutations 19, 20
• Research demonstrates that 11-19% of patients undergoing thoracic aortic aneurysm repair have a first-degree relative with similar disease 19

Surveillance Strategy Based on Initial Findings

• Even with normal aortic diameter, the patient cannot be considered free of genetic risk, especially at this young age 18
• Repeat imaging should occur every 3-5 years initially, with more frequent surveillance as the patient ages into the typical risk period (30s-40s) 18
• Surgical thresholds may be lower than standard (potentially 4.2-4.6 cm for certain genetic syndromes like Loeys-Dietz) if specific mutations are identified 19, 20

Important Caveats

• All first-degree relatives of affected individuals should undergo aortic imaging regardless of genetic testing results 16, 17, 19
• If genetic testing identifies a pathogenic variant, only relatives carrying the mutation require ongoing surveillance 16, 17
• Second-degree relatives should be screened if multiple first-degree relatives are affected, which applies to this case 19

Risk Assessment for Hereditary Aortic and Valve Malformations

Introduction to Hereditary Aortic and Valve Malformations

• A patient with a family history of hereditary aortic and valve malformations has a substantial risk of harboring significant disease that requires immediate echocardiographic screening, according to the American Heart Association, as the risk is high enough that first-degree relatives of affected individuals should undergo aortic imaging regardless of symptoms or initial findings 21, 22

Why Normal Exam and ECG Are Insufficient

• Thoracic aortic disease is typically asymptomatic until life-threatening events occur, making physical examination and ECG inadequate screening tools, as stated by the American College of Cardiology 21, 22
• Nine percent of patients with Bicuspid aortic valve (BAV) have affected family members, indicating strong familial clustering, as reported by the American Heart Association 21, 22

Quantifying the Risk

• Twenty percent of patients with BAV undergoing surgery have concurrent ascending aortic aneurysms requiring repair, according to the American College of Cardiology 21, 22
• Fifteen percent of patients with acute aortic dissection have bicuspid aortic valves, as stated by the American Heart Association 21, 22
• Most hereditary aortopathies follow autosomal dominant inheritance, conferring up to 50% risk to offspring, as reported by the American College of Medical Genetics 21, 22

Critical Considerations for Management

• Certain genetic mutations (TGFBR1, TGFBR2) predispose to dissection at smaller aortic diameters (<5.0 cm) or even normal diameters, making early detection critical, according to the American College of Medical Genetics 23, 21
• Both the aortic root and ascending thoracic aorta must be evaluated for evidence of aortic dilatation if Bicuspid aortic valve is identified, as stated by the American College of Cardiology 21, 22
• Family members can have thoracic aortic aneurysms even in the absence of bicuspid aortic valves, as reported by the American Heart Association 21, 22
• Do not rely on symptoms or physical findings to exclude significant disease—aortic complications often present catastrophically without warning, according to the American College of Cardiology 21, 22
• Surgical thresholds may be lower than standard (potentially 4.2-4.6 cm for Loeys-Dietz syndrome) if specific mutations are identified, as stated by the American College of Medical Genetics 23